586 related articles for article (PubMed ID: 11359904)
1. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
Kreuz S; Siegmund D; Scheurich P; Wajant H
Mol Cell Biol; 2001 Jun; 21(12):3964-73. PubMed ID: 11359904
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD).
Wajant H; Haas E; Schwenzer R; Muhlenbeck F; Kreuz S; Schubert G; Grell M; Smith C; Scheurich P
J Biol Chem; 2000 Aug; 275(32):24357-66. PubMed ID: 10823821
[TBL] [Abstract][Full Text] [Related]
3. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.
Okano H; Shiraki K; Inoue H; Kawakita T; Yamanaka T; Deguchi M; Sugimoto K; Sakai T; Ohmori S; Fujikawa K; Murata K; Nakano T
Lab Invest; 2003 Jul; 83(7):1033-43. PubMed ID: 12861043
[TBL] [Abstract][Full Text] [Related]
4. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
5. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
6. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells.
Jönsson G; Paulie S; Grandien A
Anticancer Res; 2003; 23(2B):1213-8. PubMed ID: 12820373
[TBL] [Abstract][Full Text] [Related]
7. cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells.
Cottet S; Dupraz P; Hamburger F; Dolci W; Jaquet M; Thorens B
Diabetes; 2002 Jun; 51(6):1805-14. PubMed ID: 12031968
[TBL] [Abstract][Full Text] [Related]
8. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
Bortul R; Tazzari PL; Cappellini A; Tabellini G; Billi AM; Bareggi R; Manzoli L; Cocco L; Martelli AM
Leukemia; 2003 Feb; 17(2):379-89. PubMed ID: 12592338
[TBL] [Abstract][Full Text] [Related]
9. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes.
Wachter T; Sprick M; Hausmann D; Kerstan A; McPherson K; Stassi G; Bröcker EB; Walczak H; Leverkus M
J Biol Chem; 2004 Dec; 279(51):52824-34. PubMed ID: 15459191
[TBL] [Abstract][Full Text] [Related]
10. RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival.
Zhang L; Blackwell K; Workman LM; Chen S; Pope MR; Janz S; Habelhah H
Mol Cell Biol; 2015 Oct; 35(19):3324-38. PubMed ID: 26195820
[TBL] [Abstract][Full Text] [Related]
11. TNF Apoptosis Protection Fraction (TAPF) prevents apoptosis induced by TNF, but not by Fas or TRAIL, via NF-κB-induced increase in cFLIP.
Seol JY; Mihich E; Berleth ES
Cytokine; 2015 Oct; 75(2):321-9. PubMed ID: 26198031
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.
Oya M; Ohtsubo M; Takayanagi A; Tachibana M; Shimizu N; Murai M
Oncogene; 2001 Jun; 20(29):3888-96. PubMed ID: 11439352
[TBL] [Abstract][Full Text] [Related]
13. TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways.
Zhang L; Dittmer MR; Blackwell K; Workman LM; Hostager B; Habelhah H
Cell Signal; 2015 Feb; 27(2):306-14. PubMed ID: 25446254
[TBL] [Abstract][Full Text] [Related]
14. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
Ravi R; Bedi GC; Engstrom LW; Zeng Q; Mookerjee B; Gélinas C; Fuchs EJ; Bedi A
Nat Cell Biol; 2001 Apr; 3(4):409-16. PubMed ID: 11283615
[TBL] [Abstract][Full Text] [Related]
15. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin.
Shin EC; Seong YR; Kim CH; Kim H; Ahn YS; Kim K; Kim SJ; Hong SS; Park JH
Exp Mol Med; 2002 May; 34(2):114-22. PubMed ID: 12085986
[TBL] [Abstract][Full Text] [Related]
16. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.
Grotzer MA; Eggert A; Zuzak TJ; Janss AJ; Marwaha S; Wiewrodt BR; Ikegaki N; Brodeur GM; Phillips PC
Oncogene; 2000 Sep; 19(40):4604-10. PubMed ID: 11030149
[TBL] [Abstract][Full Text] [Related]
17. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells.
Kim YS; Schwabe RF; Qian T; Lemasters JJ; Brenner DA
Hepatology; 2002 Dec; 36(6):1498-508. PubMed ID: 12447876
[TBL] [Abstract][Full Text] [Related]
19. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.
Qin JZ; Bacon P; Chaturvedi V; Nickoloff BJ
J Invest Dermatol; 2001 Oct; 117(4):898-907. PubMed ID: 11676830
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2.
Diessenbacher P; Hupe M; Sprick MR; Kerstan A; Geserick P; Haas TL; Wachter T; Neumann M; Walczak H; Silke J; Leverkus M
J Invest Dermatol; 2008 May; 128(5):1134-47. PubMed ID: 17989734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
